Aligos Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Aligos Therapeutics, Inc. (ALGS) had Debt Securities, Available-for-sale, Amortized Cost of $39.56 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-11-06
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $39.56M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $49.51M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $88.66M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $10.00K.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-09-30 | $39.56M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $49.51M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $88.66M 10-Q · filed 2024-05-07 |
| 2023-06-30 | $10.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $24.84M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $44.58M 10-K · filed 2023-03-09 |
| 2022-09-30 | $56.20M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $88.61M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $78.95M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $19.07M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.94M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $13.03M 10-Q · filed 2021-05-10 |
| 2020-09-30 | $23.11M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |